These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Ineffectiveness of corticosteroids in cholestatic forms of chronic active hepatitis]. Degos F, Degott C, Erlinger S. Gastroenterol Clin Biol; 1980 Apr; 4(4):246-50. PubMed ID: 7188271 [Abstract] [Full Text] [Related]
23. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. Momosaki S, Nakashima Y, Kojiro M, Tabor E. J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475 [Abstract] [Full Text] [Related]
26. Comparative study of different types of treatments in chronic active hepatitis. Bahgat MH, Sabbour MS, Osman LM, Ghali AF, Gadallah MA. Chemioterapia; 1985 Jun; 4(3):227-35. PubMed ID: 2411437 [Abstract] [Full Text] [Related]
27. [Immunosuppressive therapy of chronic active hepatitis: results of a long-term follow-up]. Musca A, Cordova C, Barnaba V, Levrero M, Zaccari C, Trinchieri F, Gnecchi M. Clin Ter; 1983 Jun 15; 105(5):403-9. PubMed ID: 6872479 [No Abstract] [Full Text] [Related]
28. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. J Clin Oncol; 2009 Feb 01; 27(4):605-11. PubMed ID: 19075267 [Abstract] [Full Text] [Related]
32. [Morphologic findings in liver tissue in chronic active hepatitis B after seroconversion from HBeAg to anti-HBe]. Chlumská A, Stránský J, Taimr P, Baumruk L, Nevaril M. Vnitr Lek; 1995 Jul 01; 41(7):445-8. PubMed ID: 7571477 [Abstract] [Full Text] [Related]
33. Treatment of chronic active hepatitis--present state. The pros and cons of immunosuppressive therapy. Thaler H. Hepatogastroenterology; 1984 Feb 01; 31(1):6-11. PubMed ID: 6698488 [Abstract] [Full Text] [Related]
35. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Hepatology; 1984 Feb 01; 4(4):622-7. PubMed ID: 6745850 [Abstract] [Full Text] [Related]
36. Study of antibody to hepatitis-B virus core antigen (anti-HBc) in chronic diffuse liver disease. Dávid K, Halmy L. Acta Med Acad Sci Hung; 1982 Feb 01; 39(3-4):161-8. PubMed ID: 7185241 [Abstract] [Full Text] [Related]
37. [Immunohistochemical study of hepatitis B and D virus antigens (HBsAg, HBcAg, HDAg) in chronic liver diseases]. Horváth G, Stotz G, Schaff Z, Tolvaj G, Dávid K. Orv Hetil; 1996 May 26; 137(21):1133-8. PubMed ID: 8757107 [Abstract] [Full Text] [Related]
38. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Hepatology; 1996 Dec 26; 24(6):1327-33. PubMed ID: 8938155 [Abstract] [Full Text] [Related]